Reviva Pharmaceuticals Maintains Buy Rating and $2.00 Price Target: Chardan Capital

Chardan Capital maintains a Buy rating for Reviva Pharmaceuticals (RVPH) with a stable price target of $2.00. The latest analysis by Keay Nakae reflects continued confidence in the company's prospects. Reviva Pharmaceuticals is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases.